Myeloproliferative Neoplasms News

ASH will present the Henry M. Stratton Medal to J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD.

ASH selected 22 hematology trainees and early career faculty members to participate in this year’s ASH Clinical Research Training Institute.

Patients with pretransplantation minimal residual disease achieved comparable outcomes after receipt of a hematopoietic cell transplantation from an umbilical cord blood source or HLA–matched unrelated donor, according to retrospective study results.

The national cancer moonshot initiative’s blue ribbon panel delivered 10 recommendations to form a 5-year research blueprint to accelerate progress against cancer at the NCI’s National Cancer Advisory Board meeting.

A phase 3 study designed to evaluate pacritinib for high-risk patients with myelofibrosis met one of its primary endpoints but failed to meet another, according to the agent’s manufacturer.

The FDA granted breakthrough therapy designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Calculating percentages of bone marrow blasts from nonerythroid cells improved the prognostic assessment of patients with myelodysplastic syndrome, regardless of the presence of erythroid hyperplasia, according to study results published in Journal of Clinical Oncology.

The American Society for Radiation Oncology will hold its annual meeting from Sept. 25 to 28 in Boston.

Sexual activity and function appeared no different in cancer survivors than in cancer-free adults aged 50 years or older, according to results of a population-based study.

The approval and availability of new immunotherapy treatments sparked the need for dissemination of these therapies to patients throughout the cancer care community.